XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Condensed Balance Sheets - USD ($)
$ in Thousands
Mar. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 25,173 $ 36,964
Accounts receivable, net 125,541 122,789
Inventory 97,005 91,333
Prepaid and other current assets 18,184 16,913
Total current assets 265,903 267,999
Property and equipment, net 34,532 36,605
Goodwill 7,462 7,462
Intangible assets, net 470,668 482,350
Operating lease assets 12,462 13,353
Investment and other assets 3,211 3,141
Total assets 794,238 810,910
Current liabilities:    
Accounts payable 19,099 23,038
Accrued liabilities 113,605 119,795
Current portion of long-term debt 35,811 27,848
Other current liabilities 4,806 4,816
Total current liabilities 173,321 175,497
Long-term debt, less current portion 355,430 366,998
Deferred income taxes 1,294 1,213
Contingent consideration 18,445 18,150
Other long-term liabilities 28,316 27,934
Total liabilities 576,806 589,792
Commitments and contingencies (Note 11)
Stockholders’ Equity    
Additional paid-in capital 496,977 494,254
Accumulated deficit (326,106) (321,536)
Accumulated other comprehensive income 325 794
Total stockholders’ equity attributable to Bioventus Inc. 171,276 173,591
Noncontrolling interest 46,156 47,527
Total stockholders’ equity 217,432 221,118
Total liabilities and stockholders’ equity 794,238 810,910
Common Class A    
Stockholders’ Equity    
Common stock, value 64 63
Common Class B    
Stockholders’ Equity    
Common stock, value $ 16 $ 16